John Valliant is the founder of Fusion Pharmaceuticals. Fusion Pharmaceuticals has raised $171M in total funding. Latest round: Series B.
John Valliant is a scientist-entrepreneur and the founding CEO of Fusion Pharmaceuticals, a Canadian biotech company specializing in radioconjugates for cancer. He led the company from its inception through multiple financing rounds, a Nasdaq listing, and its acquisition by AstraZeneca.
Full founder directory · Investor directory · Company funding database · Fundraising library